newsfilter
← Latest News
GlobeNewswire·

Ocugen to Participate in Upcoming July Industry Conferences

OCGN
  • Ocugen, Inc. will present its modifier gene therapy platform at three investor and industry conferences in July 2026.
  • Dr. Shankar Musunuri, Chairman, CEO, & Co-Founder, will participate in a Fireside Chat at the Piper Sandler Virtual Ophthalmology Day on July 10, 2026, from 10:00–10:25 a.m. EDT.
  • Dr. Musunuri will join a panel on regenerative approaches in retinal disease at the OIS Retina Innovation Summit in Montreal on July 14, 2026, at 1:45 p.m. EDT.
  • At the ASRS meeting in Montreal on July 17, 2026, Arshad M. Khanani will present Phase 2 ArMaDa 1-Year Results for OCU410 from 8:21–8:24 a.m. EDT.
  • Jay Chhablani will present Phase 1/2 OCU410 quantitative FAF/SD-OCT analysis & safety outcomes at the ASRS meeting on July 17, 2026, from 8:24–8:27 a.m. EDT.
  • A webcast of the Piper Sandler presentation will be available on Ocugen's website with a replay accessible for 30 days post-event.
  • Ocugen's modifier gene therapy platform utilizes a gene-agnostic approach to address complex blindness diseases including retinitis pigmentosa, Stargardt disease, & geographic atrophy.